EGFR ABfinity™ Recombinant Rabbit Monoclonal Antibody - Purified



Catalog no. 700308

(See product label for lot information)

Clone/PAD: 30H45L48

 Isotype:
 IgG

 Gene ID:
 1956

 Protein Acc. no.:
 P00533

 Qty:
 100 μg

 Volume:
 200 μl

 Concentration:
 0.5 mg/mL

Formulation

PBS + 0.09% sodium azide

Validation

See <u>www.invitrogen.com/antibodies</u> for protocols Validated for use in WB and IF

Reactivity

Human

Immunogen

Recombinant Protein

Sequence Identity

Human

Sequence Homology

Mouse, rat and dog

Expected Reactivity

Based on sequence identity and similarity, reactivity to human, mouse, rat and dog is expected.

Storage

2-8°C for up to 1 month, -20°C for long term storage. Avoid repeated freezing and thawing.

Expiration Date

Expires one year from date of receipt when stored as instructed.

Background

Epidermal Growth Factor Receptor (EGFR) is a 175 kDa transmembrane glycoprotein which belongs to the tyrosine kinase superfamily (2, 4). EGFR acts as a receptor for epidermal growth factor (EGF) family (1, 2). Binding of EGFR to its ligands causes autophosphorylation of tyrosine kinase followed by activation of signal transduction of the pathways connected to cell proliferation and differentiation (2). Deregulation of EGFR expression has been connected to carcinogenesis and metastasis (3).

References

- Bridges, A.J. (1999). The rationale and strategy used to develop a series of highly potent, irreversible, inhibitors of the epidermal growth factor receptor family of tyrosine kinases. Current medicinal chemistry 6, 825-843.
- Herbst, R.S. (2004). Review of epidermal growth factor receptor biology. International journal of radiation oncology, biology, physics 59, 21-26.
 Khazaje K. Schirrmacher V. and Lichtner R.B. (1993). EGE

Khazaie, K., Schirrmacher, V., and Lichtner, R.B. (1993). EGF receptor in neoplasia and metastasis. Cancer metastasis reviews 12, 255-274.

- 3. Raymond, E., Faivre, S., and Armand, J.P. (2000). Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs 60 Suppl 1, 15-23; discussion 41-12.
- 4. Zwick, E., Hackel, P.O., Prenzel, N., and Ullrich, A. (1999). The EGF receptor as central transducer of heterologous signalling systems. Trends in pharmacological sciences 20, 408-412.


Following applications had been tested during development. To make sure the consistency and reliability in the future lots, each lot is tested with antigen ELISA for specificity and potency. Each lot is also tested with SDS-PAGE, to ensure high purity.

Applications:

	Species	Test Material	Concentration
Western Blotting	Human	A431	1-2 μg/ml
Immunofluorescence	Human	Hela	5-10 µg/ml


For research use only. CAUTION: Not for human or animal therapeutic or diagnostic use.

www.invitrogen.com



Western Blot of EGFR labeled with rabbit anti-EGFR (Cat. No. 700308).

Rabbit anti-EGFR (1 μ g/ml) was used to label EGFR in A431 cell lysate (30 μ g). The western was performed using the WesternBreeze® kit with NBT/BCIP as the substrate (Cat. No.WB7105).



Immunocytochemistry of HeLa cells labeled with rabbit anti-EGFR (Cat. No. 700308).

HeLa cells were labeled with rabbit anti-EGFR (10 ug/ml). Alexa Fluor® 488 goat anti-rabbit (Cat. No. A11008) was used at 1:1000 as secondary antibody. Composite image of DAPI signal (shown in blue), anti EGFR (shown in green) and Phalloidin Alexa Fluor® 594 (shown in red).

Explanation of symbols				
Symbol	Description	Symbol	Description	
REF	Catalogue Number	LOT	Batch code	
RUO	Research Use Only	IVD	In vitro diagnostic medical device	
X	Use by	ł	Temperature limitation	
***	Manufacturer	EC REP	European Community authorised representative	
[-]	Without, does not contain	[+]	With, contains	
from Light	Protect from light	Æ	Consult accompanying documents	
\bigcap_{i}	Directs the user to consult instructions for use (IFU), accompanying the product.			

For research use only. CAUTION: Not for human or animal therapeutic or diagnostic use.

www.invitrogen.com

Invitrogen Corporation • 542 Flynn Rd • Camarillo • CA 93012 • Tel: 800.955.6288 • E-mail: <u>techsupport@invitrogen.com</u>

This antibody is manufactured under a licensed process covered by Patent # 5, 599, 681.